Ben Galili1, Xavier Tekpli2, Vessela N Kristensen2, Zohar Yakhini1,3. 1. Computer Science Department, Technion - Israel Institute of Technology, Haifa, Israel. 2. Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway. 3. Arazi School of Computer Science, Interdisciplinary Center, Herzliya, Israel.
Abstract
MOTIVATION AND BACKGROUND: The patient's immune system plays an important role in cancer pathogenesis, prognosis and susceptibility to treatment. Recent work introduced an immune related breast cancer. This subtyping is based on the expression profiles of the tumor samples. Specifically, one study showed that analyzing 658 genes can lead to a signature for subtyping tumors. Furthermore, this classification is independent of other known molecular and clinical breast cancer subtyping. Finally, that study shows that the suggested subtyping has significant prognostic implications. RESULTS: In this work we develop an efficient signature associated with survival in breast cancer. We begin by developing a more efficient signature for the above-mentioned breast cancer immune-based subtyping. This signature represents better performance with a set of 579 genes that obtains an improved Area Under Curve (AUC). We then determine a set of 193 genes and an associated classification rule that yield subtypes with a much stronger statistically significant (log rank p-value < 2 × 10-4 in a test cohort) difference in survival. To obtain these improved results we develop a feature selection process that matches the high-dimensionality character of the data and the dual performance objectives, driven by survival and anchored by the literature subtyping.
MOTIVATION AND BACKGROUND: The patient's immune system plays an important role in cancer pathogenesis, prognosis and susceptibility to treatment. Recent work introduced an immune related breast cancer. This subtyping is based on the expression profiles of the tumor samples. Specifically, one study showed that analyzing 658 genes can lead to a signature for subtyping tumors. Furthermore, this classification is independent of other known molecular and clinical breast cancer subtyping. Finally, that study shows that the suggested subtyping has significant prognostic implications. RESULTS: In this work we develop an efficient signature associated with survival in breast cancer. We begin by developing a more efficient signature for the above-mentioned breast cancer immune-based subtyping. This signature represents better performance with a set of 579 genes that obtains an improved Area Under Curve (AUC). We then determine a set of 193 genes and an associated classification rule that yield subtypes with a much stronger statistically significant (log rank p-value < 2 × 10-4 in a test cohort) difference in survival. To obtain these improved results we develop a feature selection process that matches the high-dimensionality character of the data and the dual performance objectives, driven by survival and anchored by the literature subtyping.
Authors: E J Blok; E Bastiaannet; W B van den Hout; G J Liefers; V T H B M Smit; J R Kroep; C J H van de Velde Journal: Cancer Treat Rev Date: 2017-11-06 Impact factor: 12.111
Authors: Joel S Parker; Michael Mullins; Maggie C U Cheang; Samuel Leung; David Voduc; Tammi Vickery; Sherri Davies; Christiane Fauron; Xiaping He; Zhiyuan Hu; John F Quackenbush; Inge J Stijleman; Juan Palazzo; J S Marron; Andrew B Nobel; Elaine Mardis; Torsten O Nielsen; Matthew J Ellis; Charles M Perou; Philip S Bernard Journal: J Clin Oncol Date: 2009-02-09 Impact factor: 44.544
Authors: Jerry Usary; Victor Llaca; Gamze Karaca; Shafaq Presswala; Mehmet Karaca; Xiaping He; Anita Langerød; Rolf Kåresen; Daniel S Oh; Lynn G Dressler; Per E Lønning; Robert L Strausberg; Stephen Chanock; Anne-Lise Børresen-Dale; Charles M Perou Journal: Oncogene Date: 2004-10-07 Impact factor: 9.867